Dual drive coexistence of <i>ALK</i> rearrangement and <i>KRAS</i> mutation advanced lung adenocarcinoma and response to crizotinib.

导出 OA

翻译打印收藏纠错

作者： You-Cai,Zhu ^[1] ; Bing,Wan ^[2] ; Li-Xin,Wu ^[1] ; Xing-Liang,Li ^[3] ; Wen-Xian,Wang ^[4] ; Chun-Wei,Xu ^[5] ; Wu,Zhuang ^[6] ; Jian-Guo,Wei ^[7] ; Kai-Qi,Du ^[1]

作者单位： Department of Chest Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing 314000, China. ^[1] Department of Respiratory and Critical Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210002, China. ^[2] Department of Tumor Molecular Laboratory, Zhejiang Rongjun Hospital, Jiaxing 314000, China. ^[3] Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China. ^[4] Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China. ^[5] Department of Medical Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China. ^[6] Department of Pathology, Shaoxing People's Hospital, Shaoxing 312000, China. ^[7]

关键词 KRAS mutation Lung adenocarcinoma anaplastic lymphoma kinase (ALK) rearrangement next-generation sequencing (NGS)

DOI 10.21037/tcr.2019.06.23

PMID 35116907

发布时间 2022-02-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交